NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update

Criteria Change Reduces Requirements for Treatment AccessibilityMALVERN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced criteria changes by Lucet Health that increase access for patients with depression to receive transcranial magnetic stimulation (TMS), such as NeuroStar® Advanced Therapy. The policy update reduces the number of antidepressant medication attempts from four down to two prior to TMS eligibility. “I am pleased to witness the collective efforts leading to improved access

Also on site :